Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,294 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Severe Pain Clear all

Conditions: Psoriasis
Interventions: Etanercept, Placebo injections; Biological · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Irvine, California • Winston-Salem, North Carolina • Seattle, Washington

Conditions: End-stage Renal Disease, Malnutrition; Protein
Interventions: Intradialytic Parenteral Nutrition; Other
Lead sponsor: Patient Care America; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pompano Beach, Florida

Conditions: Alopecia Areata
Interventions: Ruxolitinib; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Burns, Trauma
Interventions: trauma: blood collection, healthy volunteers: blood collection, Burn: blood collection; Other
Lead sponsor: University of South Alabama; Other
Eligibility: 19 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Congenital Diaphragmatic Hernia
Interventions: BALT GOLDBALL 2 detachable latex ballon, BALTACCIBDPE100 Microcatheter, Storz fetoscopic operating sheath and miniature telescope/fetoscope; Device
Lead sponsor: Mauro H. Schenone; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2043
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)
Interventions: TAK-755; Biological
Lead sponsor: Takeda; Industry
Eligibility: 0 Years to 70 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Buffalo, New York • Durham, North Carolina + 2 more

Conditions: Tinnitus, Misophonia
Interventions: Aurora Mindfulness app versus sham; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Rosacea
Interventions: doxycycline; Drug
Lead sponsor: CollaGenex Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 7
States / cities: Omaha, Nebraska • Las Vegas, Nevada • Arlington, Texas + 4 more

Conditions: Atopic Dermatitis
Interventions: NM26-2198, Placebo; Biological · Other
Lead sponsor: Yellow Jersey Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Fountain Valley, California • Glendale, California • San Diego, California + 3 more

Conditions: Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Interventions: Fabrazyme (agalsidase beta); Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 16 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 9
States / cities: Farmington, Connecticut • Coral Springs, Florida • Kansas City, Kansas + 6 more

Conditions: Post Operative Pain
Interventions: Percocet, Xartemis; Drug
Lead sponsor: Lotus Clinical Research, LLC; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Asthma
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Osteoarthritis (OA) of the Knee
Interventions: TPX-100 200mg, Once weekly for 4 weeks, PBS; Drug · Other
Lead sponsor: OrthoTrophix, Inc; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 33
States / cities: Scottsdale, Arizona • Tucson, Arizona • Carrolton, California + 26 more

Conditions: Hemophilia B
Interventions: rFIXFc; Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Up to 17 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 11
States / cities: Sacramento, California • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more

Conditions: Hypercholesterolemia
Interventions: AVE5530, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: SARS-CoV-2 (COVID-19) Severe Pneumonia
Interventions: Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg, Placebo; Drug
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more

Conditions: Moderate-to-severe Atopic Dermatitis
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Gilbert, Arizona • Coral Gables, Florida + 7 more

Conditions: Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Criminal Behavior
Interventions: BNI Chatbot, OUD Education & Treatment Resources; Behavioral
Lead sponsor: Center for Progressive Recovery, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hidradenitis Suppurativa
Interventions: Sonelokimab (M1095), Adalimumab, Placebo; Drug · Other
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 15
States / cities: Fountain Valley, California • Los Angeles, California • Miami, Florida + 12 more

Conditions: COVID-19
Interventions: Hydroxychloroquine (HCQ); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Hemophilia A
Interventions: PEGylated Recombinant Factor VIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: COVID, Covid-19, Corona Virus Infection, Coronavirus Infection, Coronavirus-19, SARS-CoV2, SARS-CoV Infection
Interventions: Ivermectin, Doxycycline Hcl, Zinc, Vitamin D3, Vitamin C; Drug · Dietary Supplement
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Ventura, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT003 MDI, PT005 MDI, Placebo MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®), Formoterol Fumarate 12 μg (Foradil® Aerolizer®), PT001 MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Clearwater, Florida • Charlotte, North Carolina • Medford, Oregon + 1 more

Conditions: Crohn's Disease
Interventions: Certolizumab pegol, Azathioprine; Biological · Drug
Lead sponsor: Gastroenterology Research of America; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

Impact of IDPN on Nutrition Markers in Patients Receiving ICHD

Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata

Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients

Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Mindfulness Application Effects on Mental Health Symptoms in Children With Severe Tinnitus and Misophonia

Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme

An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.

Creation of Home-based Asthma Real-World Measures With Mobile Health Study

53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

COVID-19 PrEP HCW HCQ Study

BAX 855 PK-guided Dosing

Trial of Combination Therapy to Treat COVID-19 Infection

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease